{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:27:14Z","timestamp":1793784434839,"version":"4.6.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,11,15]],"date-time":"2006-11-15T00:00:00Z","timestamp":1163548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1186\/1471-244x-6-54","type":"journal-article","created":{"date-parts":[[2006,11,16]],"date-time":"2006-11-16T03:17:42Z","timestamp":1163647062000},"source":"Crossref","is-referenced-by-count":15,"title":["Treatment of polydrug-using opiate dependents during withdrawal: towards a standardisation of treatment"],"prefix":"10.1186","volume":"6","author":[{"given":"\u00d8istein","family":"Kristensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terje","family":"L\u00f8landsmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5se","family":"Isaksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John-K\u00e5re","family":"Vederhus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Clausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,11,15]]},"reference":[{"key":"183_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/clpt.1988.13","volume":"43","author":"WK Bickel","year":"1988","unstructured":"Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE: A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther. 1988, 43: 72-78.","journal-title":"Clin Pharmacol Ther"},{"key":"183_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/0376-8716(94)90093-0","volume":"36","author":"LJ Cheskin","year":"1994","unstructured":"Cheskin LJ, Fudala PJ, Johnson RE: A controlled comparison of buprenorphine and clonidine for acute detoxification from opioids. Drug Alcohol Depend. 1994, 36: 115-121. 10.1016\/0376-8716(94)90093-0.","journal-title":"Drug Alcohol Depend"},{"key":"183_CR3","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/BF02219713","volume":"241","author":"D Garcia-Borreguero","year":"1991","unstructured":"Garcia-Borreguero D, Bronisch T, Apelt S, Yassouridis A, Emrich HM: Treatment of benzodiazepine withdrawal symptoms with carbamazepine. Eur Arch Psychiatry Clin Neurosci. 1991, 241: 145-150. 10.1007\/BF02219713.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"183_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/0376-8716(94)90096-5","volume":"36","author":"L Janiri","year":"1994","unstructured":"Janiri L, Mannelli P, Persico AM, Serretti A, Tempesta E: Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend. 1994, 36: 139-145. 10.1016\/0376-8716(94)90096-5.","journal-title":"Drug Alcohol Depend"},{"key":"183_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/0740-5472(93)90024-V","volume":"10","author":"AK Nigam","year":"1993","unstructured":"Nigam AK, Ray R, Tripathi BM: Buprenorphine in opiate withdrawal: a comparison with clonidine. J Subst Abuse Treat. 1993, 10: 391-394. 10.1016\/0740-5472(93)90024-V.","journal-title":"J Subst Abuse Treat"},{"key":"183_CR6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.7326\/0003-4819-127-7-199710010-00004","volume":"127","author":"PG O'Connor","year":"1997","unstructured":"O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ: Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med. 1997, 127: 526-530.","journal-title":"Ann Intern Med"},{"key":"183_CR7","first-page":"104","volume":"39","author":"A Bleich","year":"2002","unstructured":"Bleich A, Gelkopf M, Weizman T, Adelson M: Benzodiazepine abuse in a methadone maintenance treatment clinic in Israel: characteristics and a pharmacotherapeutic approach. Isr J Psychiatry Relat Sci. 2002, 39: 104-112.","journal-title":"Isr J Psychiatry Relat Sci"},{"key":"183_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/BF02939579","volume":"168","author":"S Rooney","year":"1999","unstructured":"Rooney S, Kelly G, Bamford L, Sloan D, O'Connor JJ: Co-abuse of opiates and benzodiazepines. Ir J Med Sci. 1999, 168: 36-41.","journal-title":"Ir J Med Sci"},{"key":"183_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/0376-8716(93)90093-6","volume":"32","author":"L San","year":"1993","unstructured":"San L, Tato J, Torrens M, Castillo C, Farre M, Cami J: Flunitrazepam consumption among heroin addicts admitted for in-patient detoxification. Drug Alcohol Depend. 1993, 32: 281-286. 10.1016\/0376-8716(93)90093-6.","journal-title":"Drug Alcohol Depend"},{"key":"183_CR10","volume-title":"Detoxification and Substance Abuse Treatment. Treatment Improvement Protocol.","author":"Substance Abuse and Mental Helth Services Administration","year":"2006","unstructured":"Substance Abuse and Mental Helth Services Administration: Detoxification and Substance Abuse Treatment. Treatment Improvement Protocol. 2006"},{"key":"183_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.drugalcdep.2004.04.002","volume":"76","author":"C de Wet","year":"2004","unstructured":"de Wet C, Reed L, Glasper A, Moran P, Bearn J, Gossop M: Benzodiazepine co-dependence exacerbates the opiate withdrawal syndrome. Drug Alcohol Depend. 2004, 76: 31-35. 10.1016\/j.drugalcdep.2004.04.002.","journal-title":"Drug Alcohol Depend"},{"key":"183_CR12","first-page":"CD002025","volume-title":"Cochrane Database Syst Rev","author":"L Gowing","year":"2006","unstructured":"Gowing L, Ali R, White J: Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev. 2006, CD002025-"},{"key":"183_CR13","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/j.1360-0443.2005.01154.x","volume":"100","author":"W Ling","year":"2005","unstructured":"Ling W, Amass L, Shoptaw S, Annon JJ, Hillhouse M, Babcock D, Brigham G, Harrer J, Reid M, Muir J, Buchan B, Orr D, Woody G, Krejci J, Ziedonis D: A multi-center randomized trial of buprenorphine-naloxone versus clonidine for opioid detoxification: findings from the National Institute on Drug Abuse Clinical Trials Network. Addiction. 2005, 100: 1090-1100. 10.1111\/j.1360-0443.2005.01154.x.","journal-title":"Addiction"},{"key":"183_CR14","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1358\/dot.2004.40.7.850478","volume":"40","author":"DF Zullino","year":"2004","unstructured":"Zullino DF, Khazaal Y, Hattenschwiler J, Borgeat F, Besson J: Anticonvulsant drugs in the treatment of substance withdrawal. Drugs Today (Barc ). 2004, 40: 603-619. 10.1358\/dot.2004.40.7.850478.","journal-title":"Drugs Today (Barc )"},{"key":"183_CR15","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/clpt.1988.86","volume":"43","author":"J Bell","year":"1988","unstructured":"Bell J, Seres V, Bowron P, Lewis J, Batey R: The use of serum methadone levels in patients receiving methadone maintenance. Clin Pharmacol Ther. 1988, 43: 623-629.","journal-title":"Clin Pharmacol Ther"},{"key":"183_CR16","first-page":"316","volume":"95","author":"KL Kuhn","year":"1989","unstructured":"Kuhn KL, Halikas JA, Kemp KD: Carbamazepine treatment of cocaine dependence in methadone maintenance patients with dual opiate-cocaine addiction. NIDA Res Monogr. 1989, 95: 316-317.","journal-title":"NIDA Res Monogr"},{"key":"183_CR17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1093\/alcalc\/35.4.319","volume":"35","author":"JT Harris","year":"2000","unstructured":"Harris JT, Roache JD, Thornton JE: A role for valproate in the treatment of sedative-hypnotic withdrawal and for relapse prevention. Alcohol Alcohol. 2000, 35: 319-323.","journal-title":"Alcohol Alcohol"},{"key":"183_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0741-8329(89)90022-0","volume":"6","author":"M Hillbom","year":"1989","unstructured":"Hillbom M, Tokola R, Kuusela V, Karkkainen P, Kalli-Lemma L, Pilke A, Kaste M: Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol. 1989, 6: 223-226. 10.1016\/0741-8329(89)90022-0.","journal-title":"Alcohol"},{"key":"183_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3109\/00048678009159381","volume":"14","author":"DG Lambie","year":"1980","unstructured":"Lambie DG, Johnson RH, Vijayasenan ME, Whiteside EA: Sodium valproate in the treatment of the alcohol withdrawal syndrome. Aust N Z J Psychiatry. 1980, 14: 213-215.","journal-title":"Aust N Z J Psychiatry"},{"key":"183_CR20","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1111\/j.1530-0277.2001.tb02354.x","volume":"25","author":"JP Reoux","year":"2001","unstructured":"Reoux JP, Saxon AJ, Malte CA, Baer JS, Sloan KL: Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res. 2001, 25: 1324-1329. 10.1111\/j.1530-0277.2001.tb02354.x.","journal-title":"Alcohol Clin Exp Res"},{"key":"183_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1521-0391.1998.tb00336.x","volume":"7","author":"RN Rosenthal","year":"1998","unstructured":"Rosenthal RN, Perkel C, Singh P, Anand O, Miner CR: A pilot open randomized trial of valproate and phenobarbital in the treatment of acute alcohol withdrawal. Am J Addict. 1998, 7: 189-197.","journal-title":"Am J Addict"},{"key":"183_CR22","first-page":"950","volume":"147","author":"S Apelt","year":"1990","unstructured":"Apelt S, Emrich HM: Sodium valproate in benzodiazepine withdrawal. Am J Psychiatry. 1990, 147: 950-951.","journal-title":"Am J Psychiatry"},{"key":"183_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s002130050798","volume":"141","author":"K Rickels","year":"1999","unstructured":"Rickels K, Schweizer E, Garcia EF, Case G, DeMartinis N, Greenblatt D: Trazodone and valproate in patients discontinuing long-term benzodiazepine therapy: effects on withdrawal symptoms and taper outcome. Psychopharmacology (Berl). 1999, 141: 1-5. 10.1007\/s002130050798.","journal-title":"Psychopharmacology (Berl)"},{"key":"183_CR24","volume-title":"The ICD-10 classification of mental and behavioural disorders diagnostic criteria for research","author":"World Health Organization","year":"1993","unstructured":"World Health Organization: The ICD-10 classification of mental and behavioural disorders diagnostic criteria for research. 1993, Geneva, World Health Organization"},{"key":"183_CR25","volume-title":"Det nasjonale dokumentasjonssystemet innen tiltaksapparatet for rusmiddelmisbrukere","author":"H Lauritzen","year":"2004","unstructured":"Lauritzen H, Astrid S: Det nasjonale dokumentasjonssystemet innen tiltaksapparatet for rusmiddelmisbrukere. 2004, web"},{"key":"183_CR26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3109\/00952998709001515","volume":"13","author":"L Handelsman","year":"1987","unstructured":"Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD: Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987, 13: 293-308.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"183_CR27","first-page":"1433","volume":"75","author":"N JF","year":"1997","unstructured":"JF N: Benzodiazepines - clinical aspects on use and withdrawal. M\u00e5nedsskr Prakt L\u00e6geg\u00e6rn. 1997, 75: 1433-1443.","journal-title":"M\u00e5nedsskr Prakt L\u00e6geg\u00e6rn"},{"key":"183_CR28","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1080\/10550490490440807","volume":"13 Suppl 1","author":"L Amass","year":"2004","unstructured":"Amass L, Ling W, Freese TE, Reiber C, Annon JJ, Cohen AJ, McCarty D, Reid MS, Brown LS, Clark C, Ziedonis DM, Krejci J, Stine S, Winhusen T, Brigham G, Babcock D, Muir JA, Buchan BJ, Horton T: Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA Clinical Trials Network field experience. Am J Addict. 2004, 13 Suppl 1: S42-S66. 10.1080\/10550490490440807.","journal-title":"Am J Addict"},{"key":"183_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1080\/13556210071289","volume":"5","author":"U Schneider","year":"2000","unstructured":"Schneider U, Paetzold W, Eronat V, Huber TJ, Seifert J, Wiese B, Emrich HM: Buprenorphine and carbamazepine as a treatment for detoxification of opiate addicts with multiple drug misuse: a pilot study. Addict Biol. 2000, 5: 65-69. 10.1080\/13556210071289.","journal-title":"Addict Biol"},{"key":"183_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1055\/s-2002-34115","volume":"35","author":"J Seifert","year":"2002","unstructured":"Seifert J, Metzner C, Paetzold W, Borsutzky M, Passie T, Rollnik J, Wiese B, Emrich HM, Schneider U: Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone. Pharmacopsychiatry. 2002, 35: 159-164. 10.1055\/s-2002-34115.","journal-title":"Pharmacopsychiatry"},{"key":"183_CR31","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1474-4422(05)70224-6","volume":"4","author":"E Perucca","year":"2005","unstructured":"Perucca E: Birth defects after prenatal exposure to antiepileptic drugs. Lancet Neurol. 2005, 4: 781-786. 10.1016\/S1474-4422(05)70224-6.","journal-title":"Lancet Neurol"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-6-54\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-6-54.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-6-54","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-6-54.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,23]],"date-time":"2019-01-23T06:28:47Z","timestamp":1548224927000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-6-54"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,15]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["183"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-6-54","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,15]]},"article-number":"54"}}